Trials / Completed
CompletedNCT00411554
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 319 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sitagliptin phosphate | sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks |
| DRUG | Comparator: voglibose | voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-12-14
- Last updated
- 2016-02-05
- Results posted
- 2009-09-25
Source: ClinicalTrials.gov record NCT00411554. Inclusion in this directory is not an endorsement.